Page last updated: 2024-09-04

cyc 202 and Cardiac Toxicity

cyc 202 has been researched along with Cardiac Toxicity in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, J; Cheng, Z; Coates, S; Liu, DX; Liu, Y; Xia, P	1

Other Studies

1 other study(ies) available for cyc 202 and Cardiac Toxicity

Article	Year
Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy. The Journal of biological chemistry, 2018, 12-21, Volume: 293, Issue:51 Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Cardiotoxicity; Cell Line; Cyclin-Dependent Kinase 2; Doxorubicin; Enzyme Activation; Mice; Mitochondria; Myocytes, Cardiac; Protein Kinase Inhibitors; Rats; Roscovitine; S Phase; Up-Regulation	2018

Article

Year

Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy.

The Journal of biological chemistry, 2018, 12-21, Volume: 293, Issue:51

Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Cardiotoxicity; Cell Line; Cyclin-Dependent Kinase 2; Doxorubicin; Enzyme Activation; Mice; Mitochondria; Myocytes, Cardiac; Protein Kinase Inhibitors; Rats; Roscovitine; S Phase; Up-Regulation

2018